POR Recombinant Monoclonal Antibody

Code: CSB-RA976601A0HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, IHC, IF, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P16435

Target Names

POR

Alternative Names

NADPH--cytochrome P450 reductase (CPR) (P450R) (EC 1.6.2.4), POR, CYPOR

Species Reactivity

Human

Immunogen

A synthesized peptide from human POR protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

5G4

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Immunohistochemistry (IHC) Protocol Immunofluorescence (IF) Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

IHC image of CSB-RA976601A0HU diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.
IHC image of CSB-RA976601A0HU diluted at 1:100 and staining in paraffin-embedded human liver tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.
Immunofluorescence staining of HepG2 cell with CSB-RA976601A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
Overlay Peak curve showing HepG2 cells stained with CSB-RA976601A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

NADPH-cytochrome P450 reductase (POR) serves as the essential electron donor for all microsomal cytochrome P450 enzymes, making it a critical node in drug metabolism, steroid biosynthesis, and xenobiotic detoxification pathways. Researchers investigating hepatic metabolism, pharmacokinetics, or P450-dependent disease mechanisms require reliable detection of this membrane-bound flavoprotein to understand electron transfer dynamics and metabolic capacity in their experimental systems.

This recombinant monoclonal antibody, generated against a synthetic peptide derived from human POR, offers the reproducibility that demanding research applications require. As a sequence-defined recombinant clone, it eliminates the lot-to-lot variability inherent in traditional hybridoma-derived antibodies, ensuring your experimental conditions remain consistent across extended studies and collaborative projects.

Validation testing demonstrates robust performance across multiple detection platforms. Immunohistochemistry studies in paraffin-embedded human tissues reveal clear POR detection in both lung cancer and liver specimens at 1:100 dilution using citrate buffer antigen retrieval, with the liver staining pattern consistent with POR's known enrichment in hepatocytes where cytochrome P450 activity predominates. Immunofluorescence analysis in HepG2 hepatocellular carcinoma cells shows distinct subcellular localization, while flow cytometry experiments using the same cell line confirm reliable detection with clear separation from isotype control, providing quantitative assessment capabilities for your research.

This versatility across immunohistochemistry, immunofluorescence, and flow cytometry applications supports diverse experimental workflows, from tissue-based pathology studies to single-cell analysis. Whether you are characterizing P450 reductase expression in metabolic disease models, investigating drug-metabolizing enzyme regulation, or examining tumor metabolism, this antibody provides the consistent, validated performance your research demands.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.

Gene References into Functions

Both CYP1A2 and CYP2B4 activities were affected by their coexpression in a manner consistent with formation of the high-affinity POR-CYP1A2-CYP2B4 complex. PMID:29233819
genetic association studies in population in Scotland: data suggest, in type 2 diabetes treated with sulfonylureas, 2 SNPs in CYP2C9 (CYP2C9*2, R144C, rs1799853; CYP2C9*3, I359L, rs1057910) are associated with drug-induced hypoglycemia; an SNP in POR (POR*28, A503V, rs1057868) is associated with better response to sulfonylureas. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; POR = cytochrome p450 oxidoreductase) PMID:28656666
The POR*28 heterozygote appears to be associated with the stable dose of acenocoumarol. PMID:28592191
Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher cyclosporine dosing requirements and lower concentration/dose ratio. PMID:29135906
Suggest that hepatic POR and P450s are coregulated, and that POR plays a complex role in P450-mediated metabolism. PMID:27271371
A homodimer model can resolve the conundrum as to how cytochrome P450 oxidoreductase and cytochrome b5 compete for the same binding site on cytochrome P450c17. (Review) PMID:28000554
Compound heterozygosity of a paternal submicroscopic deletion and a maternal missense mutation in POR gene: Antley-bixler syndrome phenotype in three sibling fetuses PMID:26969897
analysis of mutations and polymorphisms in POR linked to metabolism of steroids and xenobiotics and pathology of P450 oxidoreductase deficiency (PORD) PMID:27068427
No significant differences in the distribution of haplotypes between cases and controls were detected. In conclusion, this study reveals that four SNPs in the POR gene (rs3823884, rs3898649, rs239953 and rs17685) may affect the susceptibility of smoking cessation in a Chinese Han population. PMID:27660057
analysis of the role of the active site loop in coenzyme binding and flavin reduction in cytochrome P450 reductase PMID:27461959
Current studies demonstrate that, unlike previously described mutations, A287P causes POR deficiency disorder due to conformational instability leading to proteolytic susceptibility in vivo, rather than through an inherent flavin-binding defect. PMID:27496950
population pharmacokinetic analysis identified that the combined genotype of CYP3A5-POR was the only covariant for the apparent clearance of tacrolimus PMID:26227094
Case Report: delayed diagnosis of 46, XY disorder of sex development due to P450 oxidoreductase (POR) deficiency. PMID:27376429
Interindividual variability in CYP2C19 activity is due to differences in both CYP2C19 protein content associated with gene diplotypes and the cytochrome P450 oxidoreductase content. PMID:26323597
POR rs2868177 and CYP2B6*6 variants contribute to the interindividual variability in human CYP2B6 activity, which may affect the disposition and interaction of other CYP2B6 substrate drugs PMID:27439448
For the first time, the SNP POR*37 831-35C>T was confirmed as a minor but statistically significant factor associated with inter-individual variation in warfarin maintenance dose in Han Chinese PMID:27488389
POR*28 does not significantly influence Tac pharmacokinetic parameters. PMID:26829596
the POR g.6593A>G polymorphism significantly influences CYP2B6 activity PMID:26580670
P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects PMID:26669712
POR A503V might decrease the risk of bladder cancer by reducing its metabolic activity. PMID:26123203
POR besides CYP2B6 can influence cyclophosphamide metabolism PMID:26544874
Study is a thorough structural, dynamic, and thermodynamic characterization of the soluble form of human microsomal CPR using small-angle x-ray scattering and nuclear magnetic resonance spectroscopy under various conditions PMID:25809265
This study confirmed that CYP3A5*1 was associated with lower tacrolimus trough concentrations. POR*28 was associated with decreased tacrolimus trough concentrations although the effect was small possibly through enhanced CYP3A4 enzyme activity. PMID:26067485
electron transfer between mCPR and aromatase PMID:26087061
POR is the main determinant of SN30000 sensitivity in 3 different genetic backgrounds. Head and neck squamous cell carcinomas showed heterogeneous POR expression. There may be a relationship between HPV status and hypoxia-activated prodrug sensitivity. PMID:26297733
We identified seven unreported SNP genetic variations. The p.Pro384Leu variant exhibited reduced enzymatic activities compared with wild-type. PMID:25712184
Results show that combining the CYP3A5*1, POR*28 and CYP3A4*22 genotypes allows partial differentiation of early tacrolimus dose requirements and the time to reach therapeutic target concentrations after transplantation. PMID:25322286
In children with FH, carriage of POR*28 allele is associated with reduced effect of atorvastatin on TChol and LDLc and therefore identifies FH children that may require higher atorvastatin doses to achieve full therapeutic benefits PMID:25521355
Transient kinetic dissection of the reaction of POR with NADPH and the reduction in cytochrome c by POR using stopped-flow techniques revealed defects in individual electron transfer steps mediated by A287P. PMID:25728647
Interactions of HO-2 with CPR and BVR, were evaluated. PMID:25196843
Data shows that POR*28 allele was not associated with the lipid-lowering effect of atorvastatin. PMID:24430948
results showed that the CYP2C19 and/or P450 oxidoreductase genotypes have an impact on the clearance of clobazam and/or N-desmethylclobazam PMID:24345815
NADPH-cytochrome P450 reductase is regulated by all-trans retinoic acid and by 1,25-dihydroxyvitamin D3 in human acute myeloid leukemia cells. PMID:24642534
The role of Cytochrome P450 reductase is to provide electrons to a redox partner, the interactions with cytochrome P450 2D6 (2D6) were investigated and a possible complex structure is suggested. PMID:23832577
results show that FMO3 E158K and POR A503V polymorphisms are minor sources of nicotine metabolism variation, insufficient to appreciably alter smoking. PMID:24448396
POR*28 allele is an important source of CYP2C9 activity variability and combined with CYP2C9 gene poly-morphisms may explain individual variability in the effect of sulfonylureas. PMID:24464600
Seventeen SNPs of CYP3A5, CYP3A4, COMT, IL-10 and POR were identified. PMID:24465960
Candidate-gene study shows that polymorphisms in PPARalpha and POR might predispose patients being treated with tacrolimus to the development of NODAT after kidney transplantation PMID:24113216
Findings regarding the interaction of NADPH-P450 reductase (NPR) with cellular stress response (CSR) indicated function of NPR in hypoxic response. PMID:24491563
Domain motion is linked closely to the individual steps of the catalytic cycle of cytochrome P450 reductase. PMID:23911089
although POR expression is a potential biomarker of sensitivity to some HAP, identification of other one-electron reductases responsible for HAP activation is needed for their rational clinical development. PMID:24196959
Structural, enzymatic and clinical implications of the NADPH P450 oxidoreductase mutations linked to newly identified disorders in humans, now categorized as POR deficiency[review]. PMID:23353702
POR genetic variants affect CYP2C9 activities. The impact of a POR variant on catalysis varies with the isoform of CYP2C9 and the assay substrate. PMID:22547083
Six novel NADPH-P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations were identified. PMID:22462747
The data suggested that cytochrome P450 reductase plays a major role in reactive oxygen species generation by liver cells under the basal conditions, but a minimal rike during simulated in vitro ischemia-reperfusion injury. PMID:21973081
NADPH cytochrome P450 reductase prevents this translocation and promotes oligomerization of HO-1. PMID:22545110
Studies indicate that electron transfer in cytochrome P450 reductase is conformationally gated. PMID:21762695
Clinical, biochemical, and genetic findings in a large PORD cohort. PMID:22162478
POR*28 C > T polymorphism increases 1-hydroxylation of midazolam after intravenous administration. The polymorphism is associated with increased hepatic, but not intestinal, CYP3A activity in healthy Chinese volunteers. PMID:22177374
These data indicate that the POR*28 SNP is associated with additional increases in early tacrolimus dose-requirements in patients carrying a CYP3A5*1 allele. PMID:21770725